nozepam 10 mg tabletes
olainfarm, as, latvia - oksazepāms - tablete - 10 mg
linoseptic 1 mg/10 mg/g gels
dr. august wolff gmbh & co. kg arzneimittel, germany - octenidini hydrochloridum, phenoxyethanolum - gels - 1 mg/10 mg/g
linoseptic 1 mg/20 mg/g uz ādas izsmidzināms aerosols, šķīdums
dr. august wolff gmbh & co. kg arzneimittel, germany - octenidini hydrochloridum, phenoxyethanolum - uz ādas lietojams aerosols, šķīdums - 1 mg/20 mg/g
zynteglo
bluebird bio (netherlands) b.v. - autologās cd34+ šūnu bagātināts iedzīvotāju, kas satur asinsrades cilmes šūnas, transduced ar lentiglobin bb305 lentiviral vektoru kodēšanas beta-a-t87q-globin gēnu - beta-talasēmija - other hematological agents - zynteglo ir indicēts, lai ārstētu pacientu, 12 gadi un vecāki ar asins pārliešanu atkarīgas no β thalassaemia (tdt), kas nav β0/β0 genotipa, kuriem hematopoētisko cilmes šūnu (vak) transplantācija ir lietderīgi, bet cilvēka leikocītu antigēnu (hla)-saskaņota saistīti hsc donoru nav pieejama.
herbitassin ® sūkājamas pastilas mutes dobumam ar medu un 20 augu ekstraktiem (2018.) pastila
domaco ag - pastila
halo gonseen (2017.) pulveris
dr. nona international ltd. - pulveris
korolen (paziņots) šķidrums
energy group a.s. - šķidrums
herbitassin® pastilas mutes dobumam ar augu ekstraktiem + medus (2019.) pastila
domaco dr.med aufdermaur ag - pastila
herbitassin® iceland moss + honey (2019.) pastila
domaco dr.med aufdermaur ag - pastila
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - antineoplastiski līdzekļi - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).